84057-95-4

84057-95-4 structure

Name: Ropivacaine
Chemical Name: (S)-ropivacaine
CAS Number: 84057-95-4
Molecular Formula: C₁₇H₂₆N₂O
Molecular Weight: 274.401
Catalog: API Anesthetic Agents Local anesthetics
Create Date: 2018-08-03 19:08:19
Modify Date: 2024-01-02 07:15:11
Ropivacain is a potent sodium channel blocker and acts as a local anesthetic agent. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of regional anesthesia and neuropathic pain management[1].

Name	(S)-ropivacaine
Synonyms	(S)-ROPIVACAINE HCL (2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide (S)-ROPIVACAINE HYDROCHLORIDE (S)ROPIVACAINE HYDROCHLORIDE (S)-ROPIVACAINEHYDROCHLORIDE UNII-V910P86109 (S)-(-)-ropivacaine (-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide Ropivacaine Ropivacaine hydrochloride Monohydrate (S)ROPIVACAINE HY DROCHLORIDE 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-, hydrochloride, hydrate (1:1:1) S-ROPIVACAINE HCL Ropivacaine (hydrochloride Monohydrate) (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide Ropivacaine API (+-)-ropivacaine hydrochloride (S)-ROPIVACAINEHCL (S)-(-)-1-propyl-2',6'-pipecoloxylidide S-ROPIVACAINEHCL ROPACARAINEHCL MFCD00864425 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)- RopivacaineHcl/MesylateBase Ropivacainehydrochloride Naropin Ropivacaine hydrochloride (S)-(-)-1-propyl-2',6'-pipecoloxylidine hydrochloride monohydrate l-N-n-Propylpipecolic acid-2,6-xylidide ROPIVACAINE MESYLATER (-)-1-Propyl-2',6'-pipecoloxylidide UNII-7IO5LYA57N (S)-ropivacaine hydrochloride hydrate (S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide Naropine (S)-N-propylpiperidine-2-carboxylic acid 2,6-dimethylphenyl amide ropivacaine hydrochloride hydrate Ropivacaine HCl.H2O Ropivacaine HCl S-ROPIVACAINE HYDROCHLORIDE (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide hydrochloride hydrate (2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride hydrate

Description	Ropivacain is a potent sodium channel blocker and acts as a local anesthetic agent. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of regional anesthesia and neuropathic pain management[1].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Cardiovascular Disease Research Areas >> Neurological Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel
Target	IC50: sodium ion influx[1] IC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)[2]
In Vivo	Epidural administration of Ropivacaine effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury[1]. Ropivacaine inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC)[2]. Ropivacaine prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats[2]. Ropivacaine inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs[2]. Animal Model: Adult Sprague-Dawley rats (300–400g)[1] Dosage: 1 μM Administration: Infusion (added to the perfusate reservoir) Result: Attenuated pressure-dependent increases in filtration coefficient (Kf).
References	[1]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717. [2]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321. [3]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth [4]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.

Density	1.0±0.1 g/cm3
Boiling Point	410.2±45.0 °C at 760 mmHg
Melting Point	144 - 146ºC
Molecular Formula	C₁₇H₂₆N₂O
Molecular Weight	274.401
Flash Point	201.9±28.7 °C
Exact Mass	274.204498
PSA	32.34000
LogP	3.11
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.552
Storage condition	-20℃

Hazard Codes	Xi
Risk Phrases	R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases	36/37/39-26
WGK Germany	3
RTECS	LK8650000
HS Code	2933399090

98717-15-8

~90%

84057-95-4

Literature: BRIDGE PHARMA, INC. Patent: WO2008/88756 A1, 2008 ; Location in patent: Page/Page column 34 ;

106-94-5

27262-40-4

~93%

84057-95-4

Literature: L. MOLTENI and C. DEI FRATELLI ALITTI - SOCIETA DI ESERCIZIO S.P.A. Patent: WO2006/133837 A2, 2006 ; Location in patent: Page/Page column 3-4 ;

Precursor 3
98717-15-8 106-94-5 27262-40-4
DownStream 2
98717-15-8 132112-35-7

HS Code	2933399090
Summary	2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

84057-95-4	98626-60-9
854056-07-8	98717-15-8
132112-35-7	1392208-04-6
684647-62-9	98717-16-9
1945965-95-6	247061-07-0